Hims & Hers Health.
American telehealth company
- Reports this week
- 0
- Active events
- 0
- Connections
- 115
What's happening
Earlier this month
One to three months ago
-
Soleil Boughton has been appointed as the chief legal officer of Hims & Hers Health.Some support1 report
-
Deborah M. Autor reported a disposition of Hims & Hers Health shares.Some support1 report
-
Hims & Hers Health CEO sold company shares to cover tax withholding obligations.Some support2 reports
-
Hims & Hers Health completed its largest acquisition in company history, involving Eucalyptus.Well supported3 reports
-
CVS, Amazon, and Pfizer are involved in strategic moves, with Hims & Hers Health being identified as a potential acquisition target for Amazon or Pfizer.Some support1 report
-
Partnership between Novo Nordisk and Hims & Hers Health terminated due to unauthorized drug promotion in the GLP-1 weight loss market.Well supported6 reports1 development inside
-
Hims & Hers Health and Novo Nordisk announced a collaboration regarding the development of GLP-1 weight-loss drugs.Some support1 report
Gone quiet
No new reports in 90+ days-
Hims & Hers Health and Teladoc Health, Inc. are two companies that operate in the virtual healthcare market.Some support4 reports
-
FDA interest in peptides benefits Novo Nordisk, while regulatory clarity impacts Hims & Hers Health stock.Some support1 report
-
Amundi raised its holdings in Hims & Hers Health stock on July 4, 2026.Some support1 report
-
MarketBeat highlighted Johnson & Johnson, Hims & Hers Health, and UnitedHealth Group as key investment focuses.Some support1 report1 development inside
-
MarketBeat reported analyst recommendations for the telehealth company Hims & Hers Health.Some support1 report
-
Novo Nordisk alleged Hims & Hers failed to adhere to law.Well supported9 reports4 developments inside
-
Hims & Hers Health, based in San Francisco, is offering investors economic exposure to Bitcoin.Some support1 report
-
Barclays raised price target on Hims & Hers Health and announced a partnership to sell weight-loss drugs via its platform.Some support1 report
-
Transactions involving Hims & Hers Health stock, including insider sales and institutional purchases, were disclosed to the SEC.Some support2 reports
-
Hims & Hers Health named Anant Vinjamoori as its new Chief Medical Officer (CMO).Some support1 report
-
Tandem Diabetes Care, Hims & Hers Health, and Omnicell are noted as companies operating in the healthcare technology segment.Some support1 report
-
The FTC launched a probe into Hims & Hers Health regarding its business practices.Some support7 reports
-
Novo Nordisk terminated its deal with Hims & Hers Health. Separately, HSBC upgraded Nike stock to Buy from Hold, and CoreWeave is reportedly in talks to acquire Core Scientific.Speculative2 reports
-
Hims & Hers Health and Globe Life were noted as high-growth stocks in the market in August 2025.Some support1 report
-
Zava is being acquired by Hims & Hers Health, while Lilly faces market pressure from its own price hikes and competition from Asda's online doctor.Well supported10 reports1 development inside
-
Novo Nordisk's CEO stepped down amidst market headwinds, leading to the end of the collaboration agreement with Hims & Hers Health.Some support1 report
-
Novo Nordisk ended its partnership with Hims & Hers, while AI stocks benefit from Trump tariffs and onshoring.Some support1 report
-
Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.Speculative1 report
-
Hims & Hers Health's RSI reading indicates heavy selling is exhausting itself, and Zacks ranks the company as a Buy.Speculative1 report
-
Jim Cramer shared insights on Hims & Hers Health stock on June 27, 2025.Speculative1 report
-
Hims & Hers Health and LifeMD, Inc. are expanding their direct-to-consumer virtual healthcare services into Germany, France, Ireland, and the U.K. following the ZAVA acquisition.Speculative1 report
-
Hims & Hers Health partnered with Novo Nordisk to add liraglutide and Wegovy, drawing analyst scrutiny and strategic inquiries.Speculative1 report
-
Hims & Hers management attended a conference in Boston on July 15, 2025.Some support1 report
-
Hims & Hers Health has entered the generic drug market, coinciding with the expiration of Novo Nordisk's patent and the failure of a maintenance fee.Some support2 reports
-
Omnicell, Hims & Hers Health, and Evolent Health are noted as peers operating within the healthcare technology segment.Some support5 reports2 developments inside
-
Hims & Hers Health stock underperformed the S&P 500 and tracked the decline of the Medical sector in July 2025.Some support3 reports
-
GoodRx, Hims & Hers Health, and Omnicell are noted as operating within the healthcare technology segment.Some support2 reports
-
Hims & Hers Health reported that its online channel and personalized GLP-1 offerings drove subscriber uptake and top-line revenue.Some support1 report
-
Doximity and Hims & Hers Health are two companies that operate within the telehealth industry.Some support2 reports
-
BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.Some support2 reports1 development inside
-
Patrick Carroll disposed of shares in Hims & Hers Health in August 2025.Some support2 reports
-
Amwell and Hims & Hers Health are both companies operating within the telehealth industry.Some support2 reports
-
Palantir, Hims & Hers, and Robinhood launched leveraged ETFs, alongside advancements in AI data analytics and personalized telehealth.Some support1 report
-
Hims & Hers Health operates in 13 states and the District of Columbia.Some support2 reports
-
Hims & Hers Health is expanding its operations internationally, entering the U.K. and considering further expansion into Europe.Some support2 reports
-
Hims & Hers Health established its operational model on September 3, 2025, connecting patients to licensed healthcare professionals and facilitating care via integrated electronic medical records.Some support1 report
-
Hims & Hers Health disclosed a transaction with the SEC, while Director David Wells acquired stock and TD Cowen covered the stock.Some support1 report
-
Hims & Hers Health and Netflix are competing in the broader subscription/streaming market.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Hims & Hers Health
Events traced to Hims & Hers Health, step by step, newest first- Amwell's successful South Africa mental health program may increase competition for Hims & Hers HealthAmwell's successful South Africa mental health program may increase competition for Hims & Hers HealthPossible
- FTC lawsuit and privacy claims hit Hims & Hers HealthHims & Hers Health faces legal and financial pressure from FTC lawsuitReported
Around Hims & Hers Health this week
News at the entities that move Hims & Hers Health most-
Novo Nordisk OperationalAhmad seeks funding from Novo Nordisk while David L. Cohen facilitates talks in Philadelphia, supported by Josh Shapiro's appointment.Moves Hims & Hers Health
-
Federal Trade Commission StructuralThe Federal Trade Commission blocked the proposed merger between Kroger and Albertsons due to concerns over market power.Moves Hims & Hers Health
-
SEC StructuralA company increased its holdings by 24.4% in Q1 and reported the transaction to the SEC.Moves Hims & Hers Health
-
Amazon TransactionalMajor tech companies including Apple, Amazon, and Meta are navigating the aftermath of geopolitical tensions while testing the resilience of AI trade.Moves Hims & Hers Health
-
Visa Inc. StructuralVisa Inc. announced several new partnerships, including with Solana and Circle, and Kraken launched a debit card on its network.Moves Hims & Hers Health
-
Pfizer TransactionalPfizer and Nexentis Technologies, both healthcare companies, are competing for investment, with Pfizer reporting higher revenue and earnings.Moves Hims & Hers Health
Connections
The 37 strongest of 115, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novo Nordisk Operational
The relationship is a volatile cycle of formal partnership and intense market competition over GLP-1 drugs, frequently shifting due to regulatory and competitive pressures.
-
Eucalyptus Structural
Hims & Hers Health acquired Eucalyptus, making it a subsidiary and integrating its educational operations into the company's platform.
-
Zava Structural
Hims & Hers Health acquired Zava, integrating it as a subsidiary to expand its international and customer footprint.
-
Federal Trade Commission Structural
The FTC is actively investigating and filing lawsuits against Hims & Hers regarding deceptive billing and data sharing practices.
-
Anant Vinjamoori Structural
Hims & Hers Health employs Anant Vinjamoori as Chief Marketing Officer.
-
Ireland Transactional
Hims & Hers is expanding its operations into the Irish market through acquisitions and planned launches.
-
SEC Structural
Hims & Hers Health operates under the regulatory oversight of the SEC, requiring formal filings for transactions and stock sales.
-
Northern District Transactional
A securities class action lawsuit is currently pending against Hims & Hers Health in the Northern District.
Show all 37 connections
-
Visa Inc. Structural
Visa initiated a formal monitoring program targeting Hims & Hers due to operational concerns.
-
Pfizer Transactional
Pfizer is viewed as a potential acquirer of Hims & Hers Health due to market capitalization advantages.
-
Amazon Transactional
Amazon is identified as a strategic potential acquirer of Hims & Hers Health in the health and wellness market.
-
FDA Structural
Hims & Hers specializes in compounded drugs, operating under the regulatory framework and oversight of the FDA.
-
Amundi Transactional
Amundi increased its investment holdings in Hims & Hers Health stock.
-
Amwell Operational
Amwell and Hims & Hers Health compete within the telehealth industry.
-
California Transactional
California's attorneys general joined a lawsuit involving Hims & Hers Health.
-
Food and Drug Administration Structural
Hims & Hers operates within the regulatory framework established by the FDA, which dictates market viability and product sales.
-
Cencora Operational
Cencora and Hims & Hers Health are actively competing for investment within the healthcare sector.
-
Meta Transactional
Hims & Hers shares user data with Meta.
-
Netflix Operational
The relationship is defined by active competition in the shared subscription and streaming market space.
-
Utah Operational
Utah attorneys general joined a lawsuit involving Hims & Hers Health.
-
CVS Health Transactional
CVS Health is discussed as a potential strategic acquirer of Hims & Hers Health via its Aetna/Caremark integration.
-
StockTwits Mentioned together
StockTwits functions as a social media platform where retail investors discuss the sentiment and performance of Hims & Hers Health stock.
-
David Wells Transactional
Director David Wells acquired company stock in Hims & Hers Health.
-
Barclays Mentioned together
Barclays provided financial analysis, raising its price target for Hims & Hers Health.
-
MarketBeat Mentioned together
MarketBeat utilizes its platform to highlight Hims & Hers Health as a key focus for investment analysis and recommendations.
-
Doximity Mentioned together
Both companies operate in the telehealth industry and rely on subscription revenue models.
-
Bank of America Mentioned together
no direct coupling
-
Royal Bank of Canada Mentioned together
A market analyst firm (BofA) reduced the target price for one of the two entities from $28.00 to $25.00.
-
State of Utah Transactional
State of Utah joined a lawsuit as a co-plaintiff alongside Hims & Hers Health.
-
TD Cowen Operational
TD Cowen analysts provide market coverage of Hims & Hers Health stock.
-
San Francisco Shared context
Hims & Hers Health is headquartered in San Francisco, California.
-
Los Angeles Shared context
Hims & Hers Health operates within the jurisdiction of Los Angeles, as evidenced by the County's involvement in a related lawsuit.
-
U.K. Shared context
Hims & Hers Health is expanding its operations and market presence within the U.K.
-
Narrative Shared context
Both companies operate in a data-heavy environment subject to privacy lawsuits.
-
JPMorgan Chase Transactional
The entities were involved in a transaction where a $400 million receivables facility was secured.
-
Snap Inc. Mentioned together
No direct coupling or interaction between Snap Inc. and Hims & Hers Health was observed in the evidence.
-
FED Mentioned together
No direct relationship or coupling between the Federal Reserve and Hims & Hers Health was observed in the provided evidence.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
5 events- Soleil Boughton has been appointed as the chief legal officer of Hims & Hers Health.
- Deborah M. Autor reported a disposition of Hims & Hers Health shares.
- Hims & Hers Health CEO sold company shares to cover tax withholding obligations.
- Hims & Hers Health completed its largest acquisition in company history, involving Eucalyptus.
- CVS, Amazon, and Pfizer are involved in strategic moves, with Hims & Hers Health being identified as a potential acquisition target for Amazon or Pfizer.
July 2026
4 events- Hims & Hers Health and Novo Nordisk announced a collaboration regarding the development of GLP-1 weight-loss drugs.
- FDA interest in peptides benefits Novo Nordisk, while regulatory clarity impacts Hims & Hers Health stock.
- Amundi raised its holdings in Hims & Hers Health stock on July 4, 2026.
- MarketBeat reported analyst recommendations for the telehealth company Hims & Hers Health.
Show 1 earlier month
June 2026
36 events- Partnership between Novo Nordisk and Hims & Hers Health terminated due to unauthorized drug promotion in the GLP-1 weight loss market.
- Hims & Hers Health and Teladoc Health, Inc. are two companies that operate in the virtual healthcare market.
- MarketBeat highlighted Johnson & Johnson, Hims & Hers Health, and UnitedHealth Group as key investment focuses.
- Novo Nordisk alleged Hims & Hers failed to adhere to law.
- Hims & Hers Health, based in San Francisco, is offering investors economic exposure to Bitcoin.
- Barclays raised price target on Hims & Hers Health and announced a partnership to sell weight-loss drugs via its platform.
- Transactions involving Hims & Hers Health stock, including insider sales and institutional purchases, were disclosed to the SEC.
- Hims & Hers Health named Anant Vinjamoori as its new Chief Medical Officer (CMO).
- Tandem Diabetes Care, Hims & Hers Health, and Omnicell are noted as companies operating in the healthcare technology segment.
- The FTC launched a probe into Hims & Hers Health regarding its business practices.
- Novo Nordisk terminated its deal with Hims & Hers Health. Separately, HSBC upgraded Nike stock to Buy from Hold, and CoreWeave is reportedly in talks to acquire Core Scientific.
- Hims & Hers Health and Globe Life were noted as high-growth stocks in the market in August 2025.
- Zava is being acquired by Hims & Hers Health, while Lilly faces market pressure from its own price hikes and competition from Asda's online doctor.
- Novo Nordisk's CEO stepped down amidst market headwinds, leading to the end of the collaboration agreement with Hims & Hers Health.
- Novo Nordisk ended its partnership with Hims & Hers, while AI stocks benefit from Trump tariffs and onshoring.
- Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.
- Hims & Hers Health's RSI reading indicates heavy selling is exhausting itself, and Zacks ranks the company as a Buy.
- Jim Cramer shared insights on Hims & Hers Health stock on June 27, 2025.
- Hims & Hers Health and LifeMD, Inc. are expanding their direct-to-consumer virtual healthcare services into Germany, France, Ireland, and the U.K. following the ZAVA acquisition.
- Hims & Hers Health partnered with Novo Nordisk to add liraglutide and Wegovy, drawing analyst scrutiny and strategic inquiries.
- Hims & Hers management attended a conference in Boston on July 15, 2025.
- Hims & Hers Health has entered the generic drug market, coinciding with the expiration of Novo Nordisk's patent and the failure of a maintenance fee.
- Omnicell, Hims & Hers Health, and Evolent Health are noted as peers operating within the healthcare technology segment.
- Hims & Hers Health stock underperformed the S&P 500 and tracked the decline of the Medical sector in July 2025.
- GoodRx, Hims & Hers Health, and Omnicell are noted as operating within the healthcare technology segment.
- Hims & Hers Health reported that its online channel and personalized GLP-1 offerings drove subscriber uptake and top-line revenue.
- Doximity and Hims & Hers Health are two companies that operate within the telehealth industry.
- BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.
- Patrick Carroll disposed of shares in Hims & Hers Health in August 2025.
- Amwell and Hims & Hers Health are both companies operating within the telehealth industry.
- Palantir, Hims & Hers, and Robinhood launched leveraged ETFs, alongside advancements in AI data analytics and personalized telehealth.
- Hims & Hers Health operates in 13 states and the District of Columbia.
- Hims & Hers Health is expanding its operations internationally, entering the U.K. and considering further expansion into Europe.
- Hims & Hers Health established its operational model on September 3, 2025, connecting patients to licensed healthcare professionals and facilitating care via integrated electronic medical records.
- Hims & Hers Health disclosed a transaction with the SEC, while Director David Wells acquired stock and TD Cowen covered the stock.
- Hims & Hers Health and Netflix are competing in the broader subscription/streaming market.